Search

Lei Yao

Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )

Most Active Art Unit
1642
Art Unit(s)
1642
Total Applications
1328
Issued Applications
662
Pending Applications
127
Abandoned Applications
552

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 13955595 [patent_doc_number] => 20190054141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => MOLECULAR MARKER FOR CANCER STEM CELL [patent_app_type] => utility [patent_app_number] => 16/110001 [patent_app_country] => US [patent_app_date] => 2018-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14814 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16110001 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/110001
Molecular marker for cancer stem cell Aug 22, 2018 Issued
Array ( [id] => 13607547 [patent_doc_number] => 20180355323 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => COMPOSITION FOR INDUCING DEDIFFERENTIATION INTO CANCER STEM CELLS COMPRISING RIBOSOME-ACTIVATING INHIBITOR AS ACTIVE INGREDIENT, CANCER ORGANOID CULTURE METHOD AND ANTICANCER DRUG SCREENING PLATFORM BASED THEREON [patent_app_type] => utility [patent_app_number] => 16/105978 [patent_app_country] => US [patent_app_date] => 2018-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16105978 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/105978
Composition for inducing dedifferentiation into cancer stem cells comprising ribosome-activating inhibitor as active ingredient, cancer organoid culture method and anticancer drug screening platform based thereon Aug 20, 2018 Issued
Array ( [id] => 16839538 [patent_doc_number] => 20210147550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS [patent_app_type] => utility [patent_app_number] => 16/639073 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 124241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639073 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/639073
ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS Aug 16, 2018 Abandoned
Array ( [id] => 13622213 [patent_doc_number] => 20180362658 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => ESOPHAGEAL CANCER MARKER AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/103840 [patent_app_country] => US [patent_app_date] => 2018-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48090 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16103840 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/103840
ESOPHAGEAL CANCER MARKER AND USE THEREOF Aug 13, 2018 Abandoned
Array ( [id] => 16111691 [patent_doc_number] => 20200207868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => HER3 BINDING AGENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/637201 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637201 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/637201
HER3 binding agents and uses thereof Aug 8, 2018 Issued
Array ( [id] => 18567095 [patent_doc_number] => 20230257424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => BLOOD-BRAIN BARRIER TRANSMIGRATING COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/965885 [patent_app_country] => US [patent_app_date] => 2018-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965885 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/965885
BLOOD-BRAIN BARRIER TRANSMIGRATING COMPOUNDS AND USES THEREOF Jul 30, 2018 Abandoned
Array ( [id] => 16613711 [patent_doc_number] => 20210032364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => ANTIBODIES TO M(H)DM2/4 AND THEIR USE IN DIAGNOSING AND TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/634022 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -108 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16634022 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/634022
ANTIBODIES TO M(H)DM2/4 AND THEIR USE IN DIAGNOSING AND TREATING CANCER Jul 25, 2018 Abandoned
Array ( [id] => 16806060 [patent_doc_number] => 20210128613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => ENGINEERED IMMUNE CELLS RESISTANT TO TUMOR MICROENVIRONMENT [patent_app_type] => utility [patent_app_number] => 16/629506 [patent_app_country] => US [patent_app_date] => 2018-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16629506 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/629506
Engineered immune cells resistant to tumor microenvironment Jul 19, 2018 Issued
Array ( [id] => 13841395 [patent_doc_number] => 20190024182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => Sensitivity Markers and Uses for CDK7 Inhibitors in Breast Cancers [patent_app_type] => utility [patent_app_number] => 16/038283 [patent_app_country] => US [patent_app_date] => 2018-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8008 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16038283 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/038283
Sensitivity markers and uses for CDK7 inhibitors in breast cancers Jul 17, 2018 Issued
Array ( [id] => 16808350 [patent_doc_number] => 20210130903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => TARGETING CHROMOSOMAL INSTABILITY AND DOWNSTREAM CYTOSOLIC DNA SIGNALING FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 16/629512 [patent_app_country] => US [patent_app_date] => 2018-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16629512 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/629512
Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment Jul 9, 2018 Issued
Array ( [id] => 15321131 [patent_doc_number] => 20200000895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 16/030725 [patent_app_country] => US [patent_app_date] => 2018-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16030725 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/030725
A*03 restricted peptides for use in immunotherapy against cancers and related methods Jul 8, 2018 Issued
Array ( [id] => 13522125 [patent_doc_number] => 20180312605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD) [patent_app_type] => utility [patent_app_number] => 16/028662 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16028662 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/028662
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) Jul 5, 2018 Issued
Array ( [id] => 16268823 [patent_doc_number] => 20200270310 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => MAFG AS A POTENTIAL THERAPEUTIC TARGET TO RESTORE CHEMOSENSITIVITY IN PLATINUM-RESISTANT CANCER CELLS [patent_app_type] => utility [patent_app_number] => 16/647368 [patent_app_country] => US [patent_app_date] => 2018-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647368 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/647368
MAFG AS A POTENTIAL THERAPEUTIC TARGET TO RESTORE CHEMOSENSITIVITY IN PLATINUM-RESISTANT CANCER CELLS Jul 3, 2018 Abandoned
Array ( [id] => 13795825 [patent_doc_number] => 20190011451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => METHODS AND COMPOSITIONS FOR ASSAYING BLOOD LEVELS OF LEGUMAIN [patent_app_type] => utility [patent_app_number] => 16/025607 [patent_app_country] => US [patent_app_date] => 2018-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16025607 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/025607
METHODS AND COMPOSITIONS FOR ASSAYING BLOOD LEVELS OF LEGUMAIN Jul 1, 2018 Abandoned
Array ( [id] => 16016073 [patent_doc_number] => 20200182879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => DIAGNOSIS AND TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/624654 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16624654 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/624654
Diagnosis and treatment of cancer Jun 21, 2018 Issued
Array ( [id] => 17178641 [patent_doc_number] => 11155876 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => K-ras mutations and anti-EGFr antibody therapy [patent_app_type] => utility [patent_app_number] => 16/014056 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 11896 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014056 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/014056
K-ras mutations and anti-EGFr antibody therapy Jun 20, 2018 Issued
Array ( [id] => 17287101 [patent_doc_number] => 11203641 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => Screening for anti-cancer compounds using netrin-1 activity [patent_app_type] => utility [patent_app_number] => 16/014529 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 40 [patent_no_of_words] => 15889 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 242 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014529 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/014529
Screening for anti-cancer compounds using netrin-1 activity Jun 20, 2018 Issued
Array ( [id] => 13461701 [patent_doc_number] => 20180282393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/009301 [patent_app_country] => US [patent_app_date] => 2018-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16009301 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/009301
Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers Jun 14, 2018 Issued
Array ( [id] => 13461703 [patent_doc_number] => 20180282394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/009330 [patent_app_country] => US [patent_app_date] => 2018-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52068 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16009330 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/009330
Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers Jun 14, 2018 Issued
Array ( [id] => 15831975 [patent_doc_number] => 20200131269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT BIND TO BTN1A1 OR BTN1A1-LIGANDS [patent_app_type] => utility [patent_app_number] => 16/618764 [patent_app_country] => US [patent_app_date] => 2018-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16618764 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/618764
Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands Jun 4, 2018 Issued
Menu